Interobserver Agreement of PD-L1/SP142 Immunohistochemistry and Tumor-Infiltrating Lymphocytes (TILs) in Distant Metastases of Triple-Negative Breast Cancer: A Proof-of-Concept Study. A Report on Behalf of the International Immuno-Oncology Biomarker Working Group

Van Bockstal, Mieke; Cooks, Maxine; Nederlof, Iris; Brinkhuis, Mariël; C. Dutman, Annemiek; Koopmans, Monique; Kooreman, Loes; van der Vegt, Bert; C. Verhoog, Leon; Vreuls, Celine; J. Westenend, Pieter; Kok, Marleen; J. van Diest, P.; Nauwelaers, Inne; Laudus, Nele; Denkert, Carsten; L. Rimm, David; P. Siziopikou, Kalliopi; Ely, Scott; Zardavas, Dimitrios; Roberts, Mustimbo; Floris, Giuseppe; Hartman, Johan; Ács, Balázs; Peeters, Dieter; M.S. Bartlett, John; Dequeker, Els; Salgado, Roberto; Giudici, Fabiola; Michiels, Stefan; M. Horlings, Hugo; H. M. van Deurzen, Carolien

doi:10.3390/cancers13194910

Public

Interobserver Agreement of PD-L1/SP142 Immunohistochemistry and Tumor-Infiltrating Lymphocytes (TILs) in Distant Metastases of Triple-Negative Breast Cancer: A Proof-of-Concept Study. A Report on Behalf of the International Immuno-Oncology Biomarker Working Group

Published in Cancers • Sep 29, 2021

Authors:

Mieke Van Bockstal

Maxine Cooks

Iris Nederlof

Abstract

Patients with advanced triple-negative breast cancer (TNBC) benefit from treatment with atezolizumab, provided that the tumor contains ≥1% of PD-L1/SP142-positive immune cells. Numbers of tumor-infiltrating lymphocytes (TILs) vary strongly according to the anatomic localization of TNBC metastases. W...

Subject

Triple-negative breast cancer

Concordance

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!